Rhizen pharmaceutical treatment drug for peripheral T-cell lymphoma has been recognized as an orphan drug by FDA
-
Last Update: 2017-12-27
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Source: Sina Pharmaceutical Co., Ltd announced on December 22, 2017 that the U.S Food and Drug Administration (FDA) has granted tenagisib (rp6530), a dual PI3K δ / γ inhibitor with high selectivity and oral activity, to treat orphans of peripheral T-cell lymphoma (PTCL) "We are very pleased that tenalisib, the company's highly selective and oral active dual PI3K δ / γ inhibitor, has been named by the US FDA orphan drug We hope that this will further promote the development of drugs for the treatment of peripheral T-cell lymphoma." Said Dr Swaroop vakkalanka, founder and President of rhizen pharmaceuticals FDA orphan drug recognition is a drug or biological product granted by the United States to treat rare diseases, and provides some incentives for orphan drugs, such as 7-year marketing franchise, tax credit for clinical development costs, exemption / application (Declaration) fee exemption, and the development process with the assistance of FDA orphan Product Development Office (OOPD) Tenalisib (rp6530) is a highly selective PI3K δ / γ double inhibitor with oral activity It has been studied on the transformation of enzyme, cell and whole blood effective activity In addition to inhibiting the growth of cancer cells and leukemia / lymphoma cells in primary patients, rp6530 plays an important role in regulating tumor microenvironment at clinically available concentrations Preclinical studies have shown that rp6530 reprogrammes macrophages from the immunosuppressive M2 like phenotype (oncogenic) to the inflammatory M1 like state (antitumor), which may potentially enhance checkpoint inhibitor activity or overcome resistance to these drugs Tenalisib has been approved by FDA fast track and orphan drugs for the treatment of PTCL Rhizen Pharma, headquartered in La Chaux de fonds, Switzerland, is an innovative clinical stage biopharmaceutical company dedicated to the development of new therapeutic drugs for cancer, immune and metabolic disorders Since its establishment in 2008, a variety of patent drug candidates for a variety of cancer and immune related cell pathways have been developed
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.